Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease
- PMID: 11682034
- DOI: 10.1016/s0168-8278(01)00160-x
Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease
Abstract
Background/aims: Patients with porphyria and chronic liver disease could be at high risk of developing hepatocellular carcinoma. To define the incidence of primary liver cancer and identify variables associated with the risk of cancer in patients with porphyria cutanea tarda in comparison to control patients.
Methods: Fifty-three patients with porphyria cutanea tarda were enrolled in a prospective study (median follow-up 72 +/- 54.1 months; range 12-216) and matched individually to a control case according to age (+/-5 years), sex, duration of follow up (+/- 5 years), severity of liver disease, and hepatitis C virus infection.
Results: During follow-up hepatocellular carcinoma developed in 18 patients with porphyria and in four control patients. Incidence of primary liver cancer was 4.8 and 1.3 x 100 patients/year in the overall series of patients and of controls, respectively. The cumulative probability of being tumor free was significantly lower in porphyria cutanea tarda than in matched controls (75 vs 95%). Variables independently associated with the risk of liver cancer were the presence of porphyria and cirrhosis at enrollment (Odds ratios: 5.3, 95% CI 1.4-19.3 and 3.0, 95% CI 1.2-7.6, respectively).
Conclusions: Patients with porphyria are at higher risk of developing liver cancer than matched control patients.
Similar articles
-
High prevalence of hepatitis C virus type 1b in Italian patients with Porphyria cutanea tarda.Ital J Gastroenterol Hepatol. 1997 Dec;29(6):543-7. Ital J Gastroenterol Hepatol. 1997. PMID: 9513830
-
Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda.Hepatology. 1993 Apr;17(4):551-7. doi: 10.1002/hep.1840170405. Hepatology. 1993. PMID: 7682979
-
Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association.Hepatology. 1992 Dec;16(6):1322-6. doi: 10.1002/hep.1840160603. Hepatology. 1992. PMID: 1359994
-
[Porphyria cutanea tarda, hemosiderosis and hepatocellular carcinoma: report of one case].Rev Med Chil. 2010 May;138(5):581-5. Epub 2010 Jul 12. Rev Med Chil. 2010. PMID: 20668813 Review. Spanish.
-
[Porphyria cutanea tarda and hepatitis B and C virus infection].Presse Med. 1996 Nov 2;25(33):1589-91. Presse Med. 1996. PMID: 8952673 Review. French.
Cited by
-
Update in global trends and aetiology of hepatocellular carcinoma.Contemp Oncol (Pozn). 2018;22(3):141-150. doi: 10.5114/wo.2018.78941. Epub 2018 Sep 30. Contemp Oncol (Pozn). 2018. PMID: 30455585 Free PMC article. Review.
-
Hereditary pancreatic and hepatobiliary cancers.Int J Surg Oncol. 2011;2011:154673. doi: 10.1155/2011/154673. Epub 2011 Jun 28. Int J Surg Oncol. 2011. PMID: 22312493 Free PMC article.
-
Epidemiology and surveillance for hepatocellular carcinoma: New trends.J Hepatol. 2020 Feb;72(2):250-261. doi: 10.1016/j.jhep.2019.08.025. J Hepatol. 2020. PMID: 31954490 Free PMC article. Review.
-
Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis.Am J Pathol. 2010 Feb;176(2):1006-17. doi: 10.2353/ajpath.2010.090249. Epub 2009 Dec 17. Am J Pathol. 2010. PMID: 20019189 Free PMC article.
-
Lgr5 + cell fate regulation by coordination of metabolic nuclear receptors during liver repair.Theranostics. 2022 Aug 15;12(14):6130-6142. doi: 10.7150/thno.74194. eCollection 2022. Theranostics. 2022. PMID: 36168631 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical